Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Sep 21, 2015

Lytix Biopharma's MoA paper describes LTX-315 as a mitochondrion-targeted oncolytic peptide.

The MoA paper is published in Oncotarget.

Read the paper